CATX - שווי שוק לנפח מכירות Perspective Tx

Perspective Therapeutics is implementing robotic screening to accelerate testing, leading the targeted alpha therapy tumor segment. The EV/Revenue multiple clearly demonstrates market expectations, while the 433.20 level captures the latest indicator values. Business development relies on a team of elite physicists and oncologists, who are retained through generous RSU programs and cutting-edge laboratories.

The P/S multiple determines the market value of a business relative to its revenue, capturing the company's ability to pass inflationary costs onto product prices in a high-cost-of-capital environment. By analyzing the chronology of P/S values, an investor assesses the fairness of the asset's valuation, which is critical for Perspective Therapeutics (CATX) due to the rigid operating schedules of radiopharmaceutical laboratories and the impermissibility of downtime for high-tech synthesis lines.